All In Biotech

Drug Trial Radar · NCT05107115

Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine

A Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Phase 2 Study of Rilzabrutinib Followed by an Open-label Extension Phase in Patients With Moderate-to-severe Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment

Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Nov 24, 2021

Primary completion

Jul 19, 2023

Study completion Apr 23, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The first phase of this study will be a parallel, 12-week treatment, Phase 2, double-blind, 4 arm study to assess the safety and effectiveness of 3 oral doses of SAR444671 (rilzabrutinib), i.e. dose A, B and C, compared with placebo for decreasing the frequency and severity of itch and urticaria in male and female participants aged 18 years inclusive or older with CSU. After completion of the double-blind phase of the study, participants will be given the option of enrolling in the 40-week open label extension (OLE) phase of the study. Participants will receive open-label rilzabrutinib at dose B or dose C (the dose may be modified based on the 12-week safety and efficacy data). Due to the fact that some participants may be receiving rilzabrutinib for the first time, all participants will be monitored at Week 14, Week 16, Week 20, and Week 24. Afterwards, participants will be monitored at Week 36 and Week 52.

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • rilzabrutinibDrug

    Tablet, oral use

  • placeboDrug

    Tablet, oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12Time frame: Baseline and Week 12
  2. Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12Time frame: Baseline and Week 12

Locations

128 sites in 13 countries. Site status is shown where the registry gives one.

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number :0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320006

    CABA, Buenos Aires, Argentina

  • Investigational Site Number :0320006

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 0320002

    CABA, Buenos Aires, Argentina

  • Investigational Site Number :0320002

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 0320005

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number :0320004

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number :0320005

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 0320003

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number :0320003

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 1240003

    Québec, Canada

  • Investigational Site Number :1240003

    Québec, Canada

  • Investigational Site Number :1240010

    Calgary, Alberta, Canada

  • Investigational Site Number : 1240009

    Red Deer, Alberta, Canada

  • Investigational Site Number :1240009

    Red Deer, Alberta, Canada

  • Investigational Site Number : 1240005

    Toronto, Ontario, Canada

  • Investigational Site Number :1240005

    Toronto, Ontario, Canada

  • Investigational Site Number : 1240004

    Toronto, Ontario, Canada

  • Investigational Site Number :1240004

    Toronto, Ontario, Canada

  • Investigational Site Number : 1240006

    Montreal, Quebec, Canada

  • Investigational Site Number :1240006

    Montreal, Quebec, Canada

  • Investigational Site Number : 1240002

    Trois-Rivières, Quebec, Canada

  • Investigational Site Number :1240002

    Trois-Rivières, Quebec, Canada

  • Investigational Site Number : 1520004

    Osorno, Los Lagos Region, Chile

  • Investigational Site Number :1520004

    Osorno, Los Lagos Region, Chile

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number :1520001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number :1520003

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number :1520002

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number :2760002

    Berlin, Germany

  • Investigational Site Number : 2760002

    Berlin, Germany

  • Investigational Site Number : 2760001

    Dresden, Germany

  • Investigational Site Number :2760001

    Dresden, Germany

  • Investigational Site Number : 2760005

    Kiel, Germany

  • Investigational Site Number :2760005

    Kiel, Germany

  • Investigational Site Number : 2760004

    Mainz, Germany

  • Investigational Site Number :2760004

    Mainz, Germany

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.